<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27798">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744833</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1271-220</org_study_id>
    <nct_id>NCT02744833</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)</brief_title>
  <official_title>A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety profile of GMI-1271 and its effect on thrombus
      resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of GMI-1271 in patients with calf-level DVT by assessment with vital signs, standard laboratory blood tests, electrocardiogram, and adverse event evaluation.</measure>
    <time_frame>19 days</time_frame>
    <description>Adverse events will be assessed via Common Terminology Criteria for Adverse Events (CTCAE 4.03).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of GMI-1271 on thrombus resolution or stabilization as measured by Doppler ultrasound</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of GMI-1271 on the incidence of bleeding time</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of GMI-1271 on bleeding markers such as Prothrombin time (PT)</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of GMI-1271 on biomarkers of coagulation</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>GMI-1271</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin Sodium (Lovenox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <arm_group_label>GMI-1271</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin Sodium (Lovenox®)</intervention_name>
    <arm_group_label>Enoxaparin Sodium (Lovenox®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Male or female

          -  Diagnosed with acute isolated calf vein Deep Venous Thrombosis (DVT)

          -  Willing and able to participate in all required evaluations and procedures in this
             study protocol

        Exclusion Criteria:

          -  History or presence of clinically significant medical condition or disease in the
             opinion of the principal investigator

          -  Uncontrolled acute life-threatening bacterial, viral or fungal infection

          -  Unable to be treated with systemic anticoagulants

          -  Current use of immunosuppressants, antiplatelets (other than aspirin),
             anticoagulants, and/or anti-epileptics

          -  Diagnosis of acute leukemia or multiple myeloma undergoing active treatment or
             maintenance treatment within the past 5 years

          -  Current or recent cancer treatment

          -  Major surgery within 21 days or planned surgery during the study period

          -  Female subjects who are pregnant or breastfeeding

          -  Known history of HIV, Hepatitis B or Hepatitis C

          -  Alcoholism or drug use

          -  Clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suman Sood, MD</last_name>
    <email>sumisood@med.umichu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suman Sood, MD</last_name>
      <email>sumisood@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Blackburn</last_name>
      <phone>734-936-8556</phone>
      <email>susblac@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suman Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 8, 2016</lastchanged_date>
  <firstreceived_date>April 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
